A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer
A Phase 2 Study of Docetaxel Plus Apalutamide in Castration-Resistant Prostate Cancer Patients Post Abiraterone Acetate
Sponsor: Dana-Farber Cancer Institute
Terminated
Safety concerns
Other terminated trials from Dana-Farber Cancer Institute
Other Prostate Cancer trials with similar outcome
Listed as NCT03093272, this PHASE2 trial focuses on Prostate Cancer and remains terminated or withdrawn. Sponsored by Dana-Farber Cancer Institute, it has been updated 12 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE2
▶ Show 7 earlier versions
-
May 2020 — Jan 2021 [monthly]
Terminated PHASE2
-
Apr 2020 — May 2020 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Oct 2019 — Apr 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Aug 2018 — Oct 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE2
-
Aug 2017 — Jun 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
May 2017 — Aug 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Dana-Farber Cancer Institute
- Janssen Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .